三大在線醫療股高位遇阻 阿里健康及京東健康創新高後倒跌約5%
北京抗原試劑盒供不應求,刺激三大在線醫療股近期跑贏,尤其是京東健康(06618.HK)今早曾升至90.75元創近年半高終遇阻,掉頭回落,午後曾跌6.2%低見83.75元,現報84.4元,回吐5.5%。
藍籌阿里健康(00241.HK)今早高見10.14元,創逾一年高遇阻,掉頭低見9.2元,現報9.4元,倒跌4.4%。平安好醫生(01833.HK)繼本周二升至33.9元創年內新高遇阻反覆回落,今日高低見32元/29.2元,現報30.7元,倒跌2.7%。
恆指在地產分類指數急漲6.6%帶動,高見19,919,現報19,905,續漲454點或2.3%,總成交額1,637億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.